Has Anita Clayton, MD received payments from drug or device companies?

Yes. Drug and device makers reported $259,985 in general payments to Anita Clayton, MD across 280 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anita Clayton, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anita Clayton, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anita Clayton, MD

Psychiatry · Charlottesville, VANPI 1104951391

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $168,548 of the $259,985 with a category attached, or 64.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.1%. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$259,985in general payments, 2019–2025

Across 280 payments — averaging $928.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$52K
Sage Therapeutics, LLC$43K
Axsome Therapeutics, Inc.$23K
Janssen Research & Development, LLC$23K
AMAG Pharmaceuticals, Inc.$22K
Takeda Pharmaceuticals U.S.A., Inc.$21K
plus $76K from 13 others

$103,252in research payments, 2019–2025

Across 35 payments — averaging $2950.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$57K
Sage Therapeutics, LLC$19K
AMAG Pharmaceuticals, Inc.$11K
Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
Merck$8K
Takeda Pharmaceuticals U.S.A., Inc.$2K

What the payments were for

Royalty or licence$22,5009%
Consulting fees$168,54865%
Speaking & faculty fees$25,23510%
Travel & lodging$34,77013%
Food & beverage$7,6603%
Education$1,2710%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	70	$52,290
Sage Therapeutics, LLC	46	$43,481
Axsome Therapeutics, Inc.	5	$23,285
Janssen Research & Development, LLC	3	$22,500
AMAG Pharmaceuticals, Inc.	33	$21,640
Takeda Pharmaceuticals U.S.A., Inc.	12	$21,027
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	33	$20,284
Biogen	12	$12,360
Acadia Pharmaceuticals Inc	14	$11,478
Livanova USA, Inc.	6	$9,108
Janssen Scientific Affairs, LLC	18	$7,863
H. Lundbeck A S	4	$6,131
Janssen Global Services, LLC	1	$3,881
Neurocrine Biosciences, Inc.	15	$2,424
Neos Therapeutics, LP	1	$1,725
Alkermes, Inc.	3	$210
Johnson & Johnson	1	$139
Teva Pharmaceuticals USA, Inc.	2	$116
Lundbeck LLC	1	$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Auvelity$23,125
CAPLYTA$19,633
VYLEESI$17,420
VRAYLAR$16,369
NUPLAZID$11,139
VNS Therapy Symmetry Model 8103 Generator$9,108
TRINTELLIX$7,632
REXULTI$6,131
BOTOX$5,400
SPRAVATO$4,781
EXXUA$1,725
ZULRESSO$1,600
Zurzuvae$1,440
INVEGA SUSTENNA$139
INTRAROSA$110
MAKENA$110

How this compares

$259,985 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia →

Medicare billing

Part B allowed, 2024

$30,187

Medicare patients

Services billed

406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Duloxetine Hcl	32	$1,219
Bupropion XlBupropion Hcl	14	$516
Buspirone Hcl	14	$298
Sertraline Hcl	13	$249
Mirtazapine	14	$233
Lamotrigine	12	$167
Trazodone Hcl	13	$147
Zolpidem Tartrate	13	$50
Clonazepam	11	$18

Paid to pharmacies, not to this prescriber.

Other psychiatry in Charlottesville

Jennifer PayneCharlottesville$43K
Niku SinghFalls Church$2.5M
David ScheidererRoanoke$2.4M
Kent McDanielGlen Allen$2.1M
Jasdeep MiglaniManassas$958K
David SpiegelNorfolk$565K
William YetterVirginia Beach$312K
Robert GardellaStaunton$201K
Timothy KaneStaunton$162K
Ralph McKenzieRoanoke$161K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →